For research use only. Not for therapeutic Use.
Gardiquimod(CAT: R065998) is a potent immunostimulatory agent known for its role as a Toll-like receptor 7 (TLR7) agonist. It is widely used in immunological research to activate innate immune responses, particularly by inducing the production of cytokines such as interferons. Gardiquimod has shown promise in antiviral research, vaccine adjuvant development, and cancer immunotherapy by enhancing the body’s immune response against tumors and infections. Its ability to mimic viral components and trigger immune pathways makes it a valuable tool in studying immune mechanisms and developing new therapeutic strategies.
| Catalog Number | R065998 |
| CAS Number | 1020412-43-4 |
| Synonyms | 4-amino-2-[(ethylamino)methyl]-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol |
| Molecular Formula | C17H23N5O |
| Purity | ≥95% |
| Storage | -20°C |
| IUPAC Name | 1-[4-amino-2-(ethylaminomethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol |
| InChI | InChI=1S/C17H23N5O/c1-4-19-9-13-21-14-15(22(13)10-17(2,3)23)11-7-5-6-8-12(11)20-16(14)18/h5-8,19,23H,4,9-10H2,1-3H3,(H2,18,20) |
| InChIKey | FHJATBIERQTCTN-UHFFFAOYSA-N |
| SMILES | CCNCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N |
